Bburgdor25kdiggserqlib

What is this test?

The Borrelia burgdorferi IgG Immunoblot test is a specialized blood test that detects IgG antibodies specifically targeting the 25kD protein of Borrelia burgdorferi, the bacteria transmitted by blacklegged ticks that causes Lyme disease. The immunoblot (also called Western blot) technique is highly specific and helps confirm Lyme disease infection, particularly after an initial screening test like ELISA shows a positive or uncertain result.

Why is this test ordered?

This test is typically ordered when: (1) a patient has symptoms suggestive of Lyme disease such as the characteristic bull's eye rash (erythema migrans), fever, headache, or joint pain; (2) a previous Lyme disease screening test (ELISA) was positive or inconclusive; (3) a healthcare provider suspects Lyme disease based on exposure history, such as being bitten by a tick or spending time in areas where Lyme disease is common. The test helps confirm whether the immune system has produced antibodies against the Lyme disease bacteria.

How is the test performed?

A healthcare professional will draw a blood sample from a vein in your arm. The blood is then sent to a laboratory where technicians use the immunoblot technique to detect specific IgG antibodies against the 25kD protein of Borrelia burgdorferi. This method separates bacterial proteins by size and uses antibodies from your blood to identify if they react to these specific proteins. The test provides a qualitative result—either positive (antibodies detected) or negative (no antibodies detected).

What do the results mean?

A positive result indicates that IgG antibodies to the 25kD protein of Borrelia burgdorferi were detected in your blood, suggesting past or current infection with the Lyme disease bacteria. A negative result means no antibodies were detected, which could mean: you do not have Lyme disease; you were infected very recently and antibodies haven't developed yet (the immune response takes 2-4 weeks); or the infection was successfully treated and antibodies have decreased. Your healthcare provider will interpret these results in conjunction with your symptoms, exposure history, and other test findings.

Are there any risks or limitations?

The risks of this test are minimal and similar to routine blood tests, including slight pain or bruising at the injection site, and rarely, infection. Limitations include: the test may be negative in early infection before antibodies develop; some people with past Lyme disease may remain positive for years; cross-reactivity with other conditions (like other bacterial or autoimmune diseases) can occasionally cause false positives; and the test cannot distinguish between current active infection and past exposure. This is why clinical symptoms and exposure history are essential for accurate interpretation.